dapt

Even when starting DAPT within 72hours of symptom onset for individuals with minor stroke or TIA the benefit of DAPT for the first 21 days was still seen at 90 day follow up in the form of less recurrent stroke

https://www.nejm.org/do/10.1056/NEJMdo007334/full/

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

• Cardiology This Week: A concise summary of recent studies
• Cardiac involvement in Fabry’s Disease
• Anti-thrombotic therapy post PCI: DAPT in 2023 
• Mythbusters: Powernap for heart health

Host: Rick Grobbee
Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger

Want to watch that episode? Go to: https://esc365.escardio.org/event/896

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes. 
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. 
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. 

Declarations of interests 

Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Franz Weidinger have declared to have no potential conflicts of interest to report. 

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. 

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. 

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Sanofi.

Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll; 
personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Equity <1% in Applied Therapeutics, Elixir Medical, Stel, ControlRad (spouse); Scientific Advisory Board for AMA, ACC (BOT Member, SC Member CTR Program), SCAI (Women in Innovations Committee Member), JAMA Cardiology Associate Editor; Faculty CRF (no fee).

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Listen in as David chats with author and nationally recognized asset protection attorney Bo Loeffler. David and Bo discuss Bo’s background as a litigator and U.S. Bankruptcy Trustee and how that has helped him as an asset protection attorney. Bo also chats about his experience in representing lottery winners.

David and Bo then dive into a few specific tools often used in asset protection planning, including insurance and exempt assets. They also cover limited liability companies (LLCs) and trusts—discussing the key success factors for each and pitfalls to avoid.

You can find show notes and more information by visiting www.physicianswealthpodcast.com. 

Estate planning experts discuss the gifting risks for moderate estates that want the flexibility to access assets in the future.

The American College of Trust and Estate Counsel, ACTEC, is a professional society of peer-elected trust and estate lawyers in the United States and around the globe. This series offers professionals best practice advice, insights and commentary on subjects that affect the profession and clients. Learn more in this podcast.

Smoking and inactivity are the most powerful lifestyle risk factors after an MI

Insufficient activity beats out obesity or above-target LDL cholesterol.

Ticagrelor monotherapy tops DAPT for high-risk PCI patients

TWILIGHT findings support move to shorter dual-antiplatelet therapy.

Panel releases guidelines for red meat, processed meat consumption

"This assessment may be excessively pessimistic; indeed, we hope that is the case."

Remember that preeclampsia has a ‘fourth trimester’

Delivering the baby doesn’t always cure the hypertension.

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeCardio